慢性肺病患者中的 COVID-19 。
COVID-19 in Patients with Chronic Lung Disease.
机构信息
University of Nottingham, Medical School, Nottingham NG7 2UH, United Kingdom.
National Heart and Lung Institute, Imperial College London, Guy Scadding Building, Cale Street, London SW3 6LY, United Kingdom.
出版信息
Clin Chest Med. 2023 Jun;44(2):385-393. doi: 10.1016/j.ccm.2022.11.013. Epub 2022 Nov 22.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that causes an acute respiratory tract infection known as coronavirus disease 2019 (COVID-19). SARS-CoV-2 enters cells by binding the ACE2 receptor and coreceptors notably TMPRSS2 or Cathepsin L. Severe COVID-19 infection can lead to acute lung injury. Below we describe the current evidence of the impact of common chronic lung diseases (CLDs) on the development of COVID-19. The impact of treatment of CLD on COVID-19 and any risk of vaccination in patients with CLD are considered.
摘要
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）是一种新型冠状病毒，可引起急性呼吸道感染，称为 2019 年冠状病毒病（COVID-19）。SARS-CoV-2 通过结合 ACE2 受体和辅助受体（特别是 TMPRSS2 或组织蛋白酶 L）进入细胞。严重的 COVID-19 感染可导致急性肺损伤。下面我们描述了常见慢性肺部疾病（CLD）对 COVID-19 发展的影响的现有证据。还考虑了 CLD 治疗对 COVID-19 的影响以及 CLD 患者接种疫苗的任何风险。
相似文献
1
COVID-19 in Patients with Chronic Lung Disease.
Clin Chest Med. 2023 Jun;44(2):385-393. doi: 10.1016/j.ccm.2022.11.013. Epub 2022 Nov 22.
2
Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart.
Cardiovasc Res. 2020 Aug 1;116(10):1733-1741. doi: 10.1093/cvr/cvaa191.
3
Pathophysiological conditions induced by SARS-CoV-2 infection reduce ACE2 expression in the lung.
Front Immunol. 2022 Nov 4;13:1028613. doi: 10.3389/fimmu.2022.1028613. eCollection 2022.
4
COVID-19 Severity and Mortality in Veterans with Chronic Lung Disease.
Ann Am Thorac Soc. 2024 Jul;21(7):1034-1043. doi: 10.1513/AnnalsATS.202311-974OC.
5
Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial Cells and in Human Nasal Epithelial Cells.
Int J Mol Sci. 2023 Feb 7;24(4):3288. doi: 10.3390/ijms24043288.
6
Comprehensive analysis of two potential novel SARS-CoV-2 entries, TMPRSS2 and IFITM3, in healthy individuals and cancer patients.
Int J Biol Sci. 2020 Sep 30;16(15):3028-3036. doi: 10.7150/ijbs.51234. eCollection 2020.
7
Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells.
J Allergy Clin Immunol. 2020 Jul;146(1):80-88.e8. doi: 10.1016/j.jaci.2020.05.004. Epub 2020 May 15.
8
Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
Am J Physiol Lung Cell Mol Physiol. 2020 Aug 1;319(2):L325-L336. doi: 10.1152/ajplung.00189.2020. Epub 2020 Jul 8.
9
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology.
J Thorac Oncol. 2021 Nov;16(11):1821-1839. doi: 10.1016/j.jtho.2021.07.002. Epub 2021 Jul 16.
10
ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2.
Hypertension. 2020 Sep;76(3):651-661. doi: 10.1161/HYPERTENSIONAHA.120.15595. Epub 2020 Aug 12.
引用本文的文献
1
Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: "Symptom Rebound".
Viruses. 2025 May 29;17(6):782. doi: 10.3390/v17060782.
2
Demographic and regional trends of sepsis mortality in the United States, 1999-2022.
BMC Infect Dis. 2025 Apr 11;25(1):504. doi: 10.1186/s12879-025-10921-7.
3
Comparative analysis of COVID-19-related mortality risk in chronic lower respiratory disease and interstitial lung disease.
Sarcoidosis Vasc Diffuse Lung Dis. 2024 Dec 10;41(4):e2024057. doi: 10.36141/svdld.v41i4.16139.
4
TAS2R38 Genotype Does Not Affect SARS-CoV-2 Infection in Primary Ciliary Dyskinesia.
Int J Mol Sci. 2024 Aug 8;25(16):8635. doi: 10.3390/ijms25168635.
5
Cell-surface d-glucuronyl C5-epimerase binds to porcine deltacoronavirus spike protein facilitating viral entry.
J Virol. 2024 Aug 20;98(8):e0088024. doi: 10.1128/jvi.00880-24. Epub 2024 Jul 30.
6
Effects of the Novel Coronavirus Pandemic on the Identification and Care of Critically Ill Emergency Patients Not Infected with COVID-19.
Risk Manag Healthc Policy. 2023 Dec 4;16:2661-2672. doi: 10.2147/RMHP.S437690. eCollection 2023.
本文引用的文献
1
COVID-19 mRNA Vaccines and Interstitial Lung Disease Exacerbation: Causation or Just a Temporal Association?
Am J Respir Crit Care Med. 2022 Oct 1;206(7):919. doi: 10.1164/rccm.202205-0902LE.
2
Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis.
ERJ Open Res. 2022 May 3;8(2). doi: 10.1183/23120541.00082-2022. eCollection 2022 Apr.
3
Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis.
J Cyst Fibros. 2022 May;21(3):e184-e187. doi: 10.1016/j.jcf.2022.04.004. Epub 2022 Apr 14.
4
COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med. 2022 Jul 15;206(2):219-221. doi: 10.1164/rccm.202112-2765LE.
5
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis.
Lancet Respir Med. 2022 May;10(5):447-458. doi: 10.1016/S2213-2600(21)00511-7. Epub 2022 Mar 10.
6
Different pathogenesis of SARS-CoV-2 Omicron variant in wild-type laboratory mice and hamsters.
Signal Transduct Target Ther. 2022 Feb 25;7(1):62. doi: 10.1038/s41392-022-00930-2.
7
Deciphering Respiratory-Virus-Associated Interferon Signaling in COPD Airway Epithelium.
Medicina (Kaunas). 2022 Jan 13;58(1):121. doi: 10.3390/medicina58010121.
8
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.
Clin Microbiol Infect. 2022 Feb;28(2):163-177. doi: 10.1016/j.cmi.2021.09.036. Epub 2021 Nov 17.
9
The Promoter Polymorphism Associates With Severe COVID-19 in the European Population.
Front Med (Lausanne). 2021 Nov 23;8:668024. doi: 10.3389/fmed.2021.668024. eCollection 2021.
10
Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial.
JAMA Intern Med. 2022 Jan 1;182(1):42-49. doi: 10.1001/jamainternmed.2021.6759.
Zotero 插件